During the past decade, Alberta Health Services conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 4 clinical trials were completed, i.e. on average, 18.2% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 2 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Alberta Health Services" #1 sponsor was "Actelion" with 3 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "Ottawa Hospital Research Institute" with 2 trials sponsored and "Afexa Life Sciences Inc" with 2 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Alberta Health Services" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 4 trials as a collaborator, "Alberta Health services" with 3 trials as a collaborator, "University of Toronto" with 3 trials as a collaborator, "Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network" with 2 trials as a collaborator and "McMaster University" with 2 trials as a collaborator. Other collaborators include 35 different institutions and companies that were collaborators in the rest 43 trials.

According to Clinical.Site data, the most researched conditions in "Alberta Health Services" are "Hypertension" (2 trials), "Venous Thromboembolism" (2 trials), "Alström Syndrome (AS)" (1 trials), "Amyloidosis" (1 trials) and "Any Solid Tumor With an EZH2 GOF Mutation" (1 trials). Many other conditions were trialed in "Alberta Health Services" in a lesser frequency.

Most popular intervention types in "Alberta Health Services" are "Drug" (17 trials), "Other" (8 trials), "Device" (2 trials), "Biological" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Daratumumab" (2 trials), "Acetylsalicyclic acid 81 mg tablet qd" (1 trials), "Angiotensin II Receptor Blockers" (1 trials) and "Angiotensin converting enzyme inhibitor" (1 trials). Other intervention names were less common.

The vast majority of trials in "Alberta Health Services" are 31 trials for "All" genders.

Currently, there are NaN active trials in "Alberta Health Services". undefined are not yet recruiting, 8 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Alberta Health Services, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Alberta Health Services, 3 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 6 trials that are defined as “Not Applicable".